11:30 AM EDT, 06/25/2024 (MT Newswires) -- Optimi Health ( OPTHF ) on Tuesday said it received three export permits from Health Canada to supply MDMA and psilocybin capsules for use in patients participating in Australia's Authorised Prescriber Scheme.

Beginning with 160 doses, the licenses mark Optimi's commercial entry into Australia with its GMP (Good Manufacturing Practices) psychedelic medicines for eligible patients suffering from PTSD and Treatment-Resistant Depression. Optimi's MDMA and psilocybin capsules will be exported from its GMP-compliant production facility in Canada.

After Australia's Therapeutic Goods Administration (TGA) reclassified MDMA and psilocybin from Schedule 9 to Schedule 8 in 2023, Australia became the first country in the world to permit the use of these substances under medical supervision in a therapeutic setting.

The company's shares were last seen up $0.025 to $0.35 on the Canadian Securities Exchange.

Price: 0.35, Change: +0.03, Percent Change: +7.81